| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.14M | 4.53M | 5.72M | 5.75M | 4.78M | 4.78M |
| Gross Profit | -3.04M | -8.86M | -41.85M | -7.29M | -1.87M | -6.67M |
| EBITDA | -100.08M | -89.08M | -95.46M | -91.36M | -99.77M | -12.59M |
| Net Income | -113.30M | -103.11M | -110.57M | -104.90M | -100.96M | -14.35M |
Balance Sheet | ||||||
| Total Assets | 209.89M | 213.61M | 217.30M | 321.01M | 426.19M | 88.57M |
| Cash, Cash Equivalents and Short-Term Investments | 117.46M | 112.42M | 97.66M | 164.43M | 252.57M | 69.87M |
| Total Debt | 7.25M | 10.11M | 15.96M | 22.98M | 20.01M | 14.50M |
| Total Liabilities | 36.52M | 34.48M | 41.12M | 46.59M | 60.09M | 178.00M |
| Stockholders Equity | 173.37M | 179.13M | 176.18M | 274.41M | 366.11M | 67.00M |
Cash Flow | ||||||
| Free Cash Flow | -76.73M | -72.81M | -65.50M | -97.51M | -98.64M | -13.15M |
| Operating Cash Flow | -76.41M | -72.40M | -64.64M | -81.34M | -60.60M | -10.97M |
| Investing Cash Flow | 27.84M | -41.58M | 81.94M | -126.98M | -67.38M | -2.17M |
| Financing Cash Flow | 43.27M | 82.53M | -4.48M | 5.24M | 336.19M | 70.97M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $638.46M | ― | -57.39% | ― | 27.32% | -1.34% | |
| ― | $529.61M | ― | -38.87% | ― | ― | ― | |
| ― | $460.12M | ― | ― | ― | 15.73% | 38.73% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $407.20M | ― | -52.18% | ― | 187.52% | 26.32% | |
| ― | $326.31M | -5.12 | -26.77% | ― | ― | -24.60% | |
| ― | $734.44M | -2.08 | -77.83% | ― | ― | 43.16% |
Absci Corp. recently held its earnings call, showcasing a mixed sentiment. The company reported significant progress in clinical trials and strategic partnerships, which are pivotal in strengthening its financial position and enhancing its drug development capabilities. However, challenges such as increased R&D expenses and low revenue figures were also highlighted, indicating areas that need attention.
Absci Corporation is a clinical-stage biopharmaceutical company that leverages generative AI to advance breakthrough therapeutics, primarily focusing on drug discovery and development in the biotechnology sector.
On August 12, 2025, Absci Corporation announced its second quarter financial results and business updates, highlighting a strengthened balance sheet with $64 million raised in July 2025, sufficient to fund operations into 2028. The company expanded its collaboration with Almirall, focusing on dermatological indications, and reported progress in its internal pipeline, including clinical trials for ABS-101 and ABS-201. Despite a net loss of $30.6 million for the quarter, Absci continues to advance its AI Drug Creation platform and anticipates further partnerships in 2025.
The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.
On July 24, 2025, Absci Corporation announced an underwritten public offering of 16,670,000 shares of its common stock at $3.00 per share, potentially raising approximately $46.7 million, or $53.7 million if additional shares are purchased. The proceeds will support the development of Absci’s internal asset programs, investment in its Integrated Drug Creation platform, and general corporate purposes, positioning the company for further growth in the biopharmaceutical industry.
The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.